Skip to main content

Advertisement

Table 3 Summary of clinical outcome and immunological response

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Patients No. of vaccine Clinical response* PFS (days) OS (days) After vaccine ISR** (Grade) Peptide-specific CTL
        CDCA1 CDH3 KIF20A
1 16 SD 212 310 No 2 0 1+ 1+
2 8 PD 53 134 No 1 2+ 0 1+
3 18 SD 127 205 No 1 1+ 2+ 1+
4 19 SD 505 659 Yes 2 1+ 0 1+
5 27 SD 225 290 No 2 1+ 1+ 3+
6 10 SD 101 101   1 1+ 1+ 0
7 13 PD 64 164 Yes 1 2+ 1+ 2+
8 24 PD 64 353 Yes 2 3+ 3+ 3+
9 25 PD 57 380 Yes 2 2+ 3+ 2+
  1. *SD: stable disease; PD: progressive disease.
  2. **ISR: injection site reaction.